Gain detailed insights into the trading activity of Congress members for Agios Pharmaceuticals on our government trades page. Stay updated on how elected officials are investing in AGIO.

Agios Pharmaceuticals - Government Trades

Agios Pharmaceuticals

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Istanbul,,Tr,-,January,29,2021:,Novavax,Vaccine.,Syringe,Close

News

Movers

ACLS

AGIO

HALO

IRTC

LBTYB

LEGN

NEOG

NUVL

NVAX

NVDA

SMAR

TWST

VRNT

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts.

Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?

Lab.julia koblitz

Biotech

Health Care

Trading Ideas

General

Agios Pharmaceuticals shares rose after it announced its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved the primary endpoint of transfusion reduction response.

Why Is Agios Pharmaceuticals Stock Trading Higher On Monday?

Intraday Update

Markets

ADSK

ARWR

CGON

COHR

DNLI

GERN

GPCR

LQDA

NTLA

OLMA

PARA

SKYW

SMMT

SRCL

VERA

Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday

movers image

AKAN

APDN

ARCT

AUVI

CALT

CELH

CORT

CRKN

DKNG

EDBL

FWRD

GTHX

HLVX

HUBS

INSM

KUKE

LOAR

LUCY

MINM

MOMO

MRAI

MRNA

MRUS

NCPL

NUKK

NWTN

OBLG

OKLO

ONMD

OPTT

PEGY

POAI

RYDE

SINT

SMXT

SPCE

SRPT

STSS

TPHS

XCUR

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Equities

Contracts

Asset Sales

RPRX

Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier&#39;s vorasidenib to Royalty Pharma for $905 million upon FDA approval.

Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?

Close,Up,Shot,Of,Nvidia,Brand,Logo,On,Video,Card

DUOL

MNSO

NCLH

PAAS

Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

CRBP

CRBU

RBC&#39;s Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences, and Corbus Pharmaceuticals with key 2024 data readouts and trials.

Attention Biotech Investors - Stocks To Watch From RBC Global Healthcare Conference

Small Cap

Agios Pharmaceuticals Inc (NASDAQ: AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary 

Why Is Blood Disorder Focused Agios Pharmaceuticals Stock Trading Higher Today?

Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced that the Phase 2 portion of the global Phase 2/3 RISE UP study of mitapivat in sickle cell disease met its 

Agios Touts Encouraging Action From Sickle Cell Disease Study With Mitapivat

Europe Approves Agios Pharma&#39;s Mitapivat For Adult Pyruvate Kinase Deficiency Patients

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals Inc

Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $46.25, a high estimate of $53.00, and a low estimate of $33.00. This current average has increased by 30.91% from the previous average price target of $35.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1718632894_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Agios Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tessa Romero</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$53.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$53.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Agios Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Agios Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Agios Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Agios Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AGIO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Agios Pharmaceuticals analyst ratings.</a>
<h2>Discovering Agios Pharmaceuticals: A Closer Look</h2>
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
<h3>Financial Insights: Agios Pharmaceuticals</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Agios Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 46.0%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Agios Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -995.84% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Agios Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -10.49%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -9.13%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Agios Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Ratings For Agios Pharmaceuticals

Cantor Fitzgerald analyst Eric Schmidt reiterates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Overweight.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today presented detailed results from the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia in a plenary session (abstract #S104) at the European Hematology Association 2024 (EHA2024) Hybrid Congress, which is being held June 13-16, 2024, in Madrid, Spain. In a related poster presentation (abstract #P1529), the company presented additional data from the ENERGIZE study highlighting clinically meaningful improvements in health-related quality of life measures and patient-reported outcomes among patients in the mitapivat arm compared to those in the placebo arm.
The ENERGIZE study achieved its primary endpoint, with mitapivat demonstrating a statistically significant increase in hemoglobin response rate compared to placebo. Statistical significance was also achieved for both key secondary endpoints associated with change from baseline in FACIT-Fatigue Score and hemoglobin concentration. These improvements were observed across all pre-specified subgroups.

Agios Announced Earlier Results From Its  Phase 3 ENERGIZE Study Of Mitapivat In Non-Transfusion-Dependent Thalassemia; Study Achieved Its Primary Endpoint

<a href="https://docs.publicnow.com/viewDoc?hash_primary=94808CEEFD31376A3A6A2796DEEF8050584F174C" title="https://docs.publicnow.com/viewDoc?hash_primary=94808CEEFD31376A3A6A2796DEEF8050584F174C">https://docs.publicnow.com/viewDoc?hash_primary=94808CEEFD31376A3A6A2796DEEF8050584F174C</a>

Agio Pharmaceuticals Announces Poster Titled 'Improvements In Fatigue And 6-minute Walk Test In Adults With Alpha- Or Beta-non–Transfusion-dependent Thalassemia: The Phase 3 Energize Trial Of Mitapivat'

JP Morgan analyst Tessa Romero reinstates Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Neutral and announces $46 price target.

Price Target

Initiation

JP Morgan Reinstates Neutral on Agios Pharmaceuticals, Announces $46 Price Target

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$130.00</td>
<td>$620.0K</td>
<td>423</td>
<td>1.0K</td>
</tr>
<tr>
<td>ISRG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$345.00</td>
<td>$203.3K</td>
<td>88</td>
<td>258</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$74.8K</td>
<td>12.1K</td>
<td>174</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$70.00</td>
<td>$454.7K</td>
<td>26.7K</td>
<td>162</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$82.50</td>
<td>$29.0K</td>
<td>1.6K</td>
<td>108</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$25.00</td>
<td>$29.8K</td>
<td>417</td>
<td>89</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$800.00</td>
<td>$31.4K</td>
<td>115</td>
<td>85</td>
</tr>
<tr>
<td>AGIO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$40.00</td>
<td>$39.9K</td>
<td>520</td>
<td>30</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$110.00</td>
<td>$25.6K</td>
<td>465</td>
<td>5</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$55.00</td>
<td>$44.0K</td>
<td>72</td>
<td>0</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding A (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>), we observe a put option trade with bearish sentiment. It expires in 36 day(s) on July 19, 2024. Parties traded 2000 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $620.0K, with a price of $310.0 per contract. There were 423 open contracts at this strike prior to today, and today 1041 contract(s) were bought and sold. 
• Regarding ISRG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), we observe a call option sweep with bearish sentiment. It expires in 36 day(s) on July 19, 2024. Parties traded 25 contract(s) at a $345.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $203.3K, with a price of $8115.0 per contract. There were 88 open contracts at this strike prior to today, and today 258 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bearish sentiment. It expires in 218 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $20.00 strike. The total cost received by the writing party (or parties) was $74.8K, with a price of $748.0 per contract. There were 12168 open contracts at this strike prior to today, and today 174 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bearish sentiment. It expires in 582 day(s) on January 16, 2026. Parties traded 846 contract(s) at a $70.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $454.7K, with a price of $535.0 per contract. There were 26718 open contracts at this strike prior to today, and today 162 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a put option trade that happens to be bullish, expiring in 64 day(s) on August 16, 2024. This event was a transfer of 108 contract(s) at a $82.50 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $269.0 per contract. There were 1615 open contracts at this strike prior to today, and today 108 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bearish, expiring in 218 day(s) on January 17, 2025. This event was a transfer of 10 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $29.8K, with a price of $2980.0 per contract. There were 417 open contracts at this strike prior to today, and today 89 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option sweep that happens to be bearish, expiring in 155 day(s) on November 15, 2024. This event was a transfer of 11 contract(s) at a $800.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $31.4K, with a price of $2860.0 per contract. There were 115 open contracts at this strike prior to today, and today 85 contract(s) were bought and sold. 
• Regarding AGIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>), we observe a call option trade with bearish sentiment. It expires in 36 day(s) on July 19, 2024. Parties traded 50 contract(s) at a $40.00 strike. The total cost received by the writing party (or parties) was $39.9K, with a price of $799.0 per contract. There were 520 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold. 
• For ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we notice a call option trade that happens to be neutral, expiring in 36 day(s) on July 19, 2024. This event was a transfer of 45 contract(s) at a $110.00 strike. The total cost received by the writing party (or parties) was $25.6K, with a price of $570.0 per contract. There were 465 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
• Regarding GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we observe a call option trade with bearish sentiment. It expires in 8 day(s) on June 21, 2024. Parties traded 50 contract(s) at a $55.00 strike. The total cost received by the writing party (or parties) was $44.0K, with a price of $880.0 per contract. There were 72 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

GILD

Hims & Hers Health, Inc. Class A Common Stock

HIMS

ILMN

ISRG

VKTX

10 Health Care Stocks Whale Activity In Today's Session

These mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Agios Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) shares soared 29.13% in the last week after reporting that its transfusion-dependent (TD) alpha-or beta-thalassemia study <a href="https://www.benzinga.com//node/39141375">met primary endpoint</a>. Several analysts <a href="https://www.benzinga.com/quote/agio/analyst-ratings">raised their forecasts</a> after the announcement.</li>
<li>Verint Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) shares are zoomed 22.40% after the company on Tuesday reported better-than-expected Q1 financial results <a href="https://www.benzinga.com//node/39170267" target="_blank" rel="noreferrer noopener">and issued strong FY25 guidance</a>.</li>
<li>Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares gained 21.54% in the last week after the U.S. Food and Drug Administration&#8217;s advisory committee voted to recommend <a href="https://www.benzinga.com/general/biotech/24/06/39204978/novavax-stock-rallies-in-pre-market-as-company-plans-to-deliver-covid-19-vaccine-by-september">updated vaccines for JN.1-lineage of COVID-19</a>.</li>
<li>Nuvalent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>) shares rose 20.52%.</li>
<li>Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) shares increased 19.25%.</li>
<li>Twist Bioscience Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) shares jumped 18.40% after Guggenheim initiated coverage on the stock with a Buy rating <a href="https://www.benzinga.com/quote/twst/analyst-ratings" target="_blank" rel="noreferrer noopener">and announced a price target of $53</a>.</li>
<li>Smartsheet Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMAR#NYSE">SMAR</a>) shares escalated 18.01% after the company reported better-than-expected Q1 financial results and announced an<a href="https://www.benzinga.com//node/39195040" target="_blank" rel="noreferrer noopener"> inaugural $150 million share repurchase program</a>. Many analysts changed<a href="https://www.benzinga.com//node/39206468" target="_blank" rel="noreferrer noopener"> their price targets</a>.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) stock grew 14.03%  after the company<a href="https://www.benzinga.com//node/39211537" target="_blank" rel="noreferrer noopener"> raised its FY24 guidance</a>.</li>
<li>Legend Biotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) <a href="https://www.benzinga.com/quote/legn/analyst-ratings" target="_blank" rel="noreferrer noopener">shares rose 13.93%</a>.</li>
<li>Liberty Global Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBTYB#NASDAQ">LBTYB</a>) shares upped 12.48%.</li>
</ol>
Photo via Shutterstock
Also Read: <a href="https://www.benzinga.com/news/24/06/39243316/gamestop-and-nio-were-among-the-11-biggest-large-cap-losers-last-week-june-1-june-7-are-these-in-you">GameStop And NIO Were Among The 11 Biggest Large Cap Losers Last Week (June 1-June 7): Are These In Your Portfolio?</a>

WIIM

Agios Pharmaceuticals shares are trading higher after RBC Capital maintained an Outperform rating on the stock and raised its price target from $44 to $53. Also, Goldman Sachs maintained a Neutral rating on the stock and raised its price target from $33 to $53.

Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Neutral and raises the price target from $33 to $53.

Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $53

RBC Capital analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Outperform and raises the price target from $44 to $53.

RBC Capital Maintains Outperform on Agios Pharmaceuticals, Raises Price Target to $53

Shares Agios Pharmaceuticals Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) climbed after it was revealed a Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent (TD) alpha-or beta-thalassemia achieved its primary endpoint of <a href="https://www.benzinga.com/pressreleases/24/06/g39132225/agios-announces-phase-3-energize-t-study-of-mitapivat-met-primary-endpoint-and-all-key-secondary-e" target="_blank" rel="noreferrer noopener">transfusion reduction response</a>.
Statistical significance was also achieved for all key secondary endpoints evaluating additional measures of reduction of transfusion burden compared to placebo.
The 258-patient study met its primary endpoint of transfusion reduction response: TRR, defined as a ≥50% reduction in transfused red blood cell (RBC) units with a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period through Week 48 compared with baseline.
<ul>
<li>Treatment with mitapivat demonstrated a statistically significant reduction in transfusion burden compared to placebo, as measured by the TRR endpoint.</li>
<li>In the mitapivat arm, 30.4% of patients achieved a transfusion reduction response, compared to 12.6% of patients in the placebo arm.</li>
</ul>
Treatment with mitapivat also demonstrated a statistically significant reduction in additional measures of transfusion reduction response compared to placebo.
In addition, a higher proportion of patients in the mitapivat arm (9.9%) than the placebo arm (1.1%) achieved the secondary endpoint of transfusion independence.
Overall, during the 48-week double-blind period, the incidence of adverse events (AEs) was similar across mitapivat and placebo arms.
Based on the safety and efficacy data observed in ENERGIZE-T, the company will proceed with the previously stated plans of U.S. regulatory submission by the end of this year.
The company intends to submit a marketing application for Pyrukynd (mitapivat) in the U.S. by the end of 2024 based on all available data from both studies, <a href="https://www.benzinga.com/general/biotech/24/01/36468800/why-is-blood-disorder-focused-agios-pharmaceuticals-stock-trading-higher-today">including Phase 3 ENERGIZE study</a>.
The company also plans to submit marketing applications in Europe and the Gulf Cooperation Council (GCC) countries.
Price Action: AGIO shares are up 16.87% at $42.47 at last check Monday.
Photo: Julia Koblitz via Unsplash

Agios Pharmaceuticals shares are trading higher after the company reported Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved its primary endpoint of transfusion reduction response.

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday.
Shares of Stericycle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRCL#NASDAQ">SRCL</a>) rose sharply during Monday's session after the company inked a deal to be acquired by Waste Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) for approximately $7.2 billion, including debt.
Stericycle shares climbed 15% to $59.28 on Monday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares jumped 34.5% to $31.13 after Roaring Kitty on a Reddit post, shared his position on the stock.</li>
<li>MarineMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) jumped 27% to $36.16. OneWater Marine Inc. is reportedly said to be in advanced discussions to acquire MarineMax.</li>
<li>Liquidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) shares jumped 16.8% to $15.03 as the company said District Court issued favorable ruling and denied United Therapeutics&#8217; request to block YUTREPIA&#x2122; launch.</li>
<li>Olema Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) gained 15.5% to $11.18.</li>
<li>Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) gained 13.7% to $41.30 as the company reported Phase 3 results for mitapivat in reducing thalassemia transfusions.</li>
<li>Coherent Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NASDAQ">COHR</a>) rose 13.4% to $64.71 after the company announced the appointment of Jim Anderson as CEO.</li>
<li>CG Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) gained 11.8% to $36.34</li>
<li>Structure Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) gained 11.8% to $38.25 after the company reported 12-week results for obesity drug GSBR-1290, achieving significant weight loss.</li>
<li>Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) rose 11.8% to $23.9 after the company announced long-term data from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002..</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) climbed 11.6% to $4.8330. The resumption of the meme rally came on the back of Keith Gill, also known as "Roaring Kitty," disclosing a substantial position in GameStop on the r/Superstonk Reddit forum.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) rose 10.7% to $16.65.</li>
<li>Twist Bioscience Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) gained 9.8% to $45.99.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) climbed 9.2% to $3.8750.</li>
<li>Telephone and Data Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) climbed 9% to $21.67 as the company agreed to sell its wholly owned subsidiaries OneNeck IT Solutions and OneNeck Data Center to US Signal Company, LLC.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) rose 8.9% to $24.99 as the company reported topline results from pivotal Phase 3 PALISADE study of investigational plozasiran.</li>
<li>Summit Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) gained 8.8% to $9.45.</li>
<li>SkyWest, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NASDAQ">SKYW</a>) jumped 8.4% to $80.97.</li>
<li>Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) rose 8.3% to $218.39 after the company issued preliminary results and said there will be no restatement or adjustment of any audited or unaudited financial statements.</li>
<li>Denali Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNLI#NASDAQ">DNLI</a>) jumped 8.1% to $20.06 as the company said that the FDA has selected DNL126 for participation in support for clinical trials advancing rare disease therapeutics pilot program.</li>
<li>Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) gained 7.3% to $40.75.</li>
<li>Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>) rose 7.1% to $12.76 following reports suggesting Skydance is poised to announce the takeover of Paramount.</li>
<li>e.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) gained 7% to $199.99. DA Davidson analyst Linda Bolton Weiser maintained e.l.f. Beauty with a Buy and maintained a $220 price target.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) rose 5% to $126.55 after the broader sector selloff on Friday when the U.S. government imposed sanctions on the Middle East regarding AI chips.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39135495/20m-bet-on-this-energy-stock-check-out-these-3-stocks-insiders-are-buying">$20M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying</a>

Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the global Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent (TD) alpha- or beta-thalassemia achieved its primary endpoint of transfusion reduction response. Statistical significance was also achieved for all key secondary endpoints evaluating additional measures of reduction of transfusion burden compared to placebo.

Agios Pharmaceuticals Reports Phase 3 Results for Mitapivat in Reducing Thalassemia Transfusions

Shares of Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) fell sharply during Tuesday's session after the company announced the pricing of a $12 million public offering.
Applied DNA Sciences shares tumbled 67.5% to $0.6468 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares climbed 207% to $0.6579 after jumping around 13% on Friday.</li>
<li>Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) jumped 110% to $46.20 after the company announced topline results from ASPEN Phase 3 study met its primary endpoint.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) shares gained 91.5% to $0.3411 after the company on Friday announced its SUNation subsidiary signed a 1.95-megawatt project.</li>
<li>Calliditas Therapeutics AB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALT#NASDAQ">CALT</a>) shares gained 74.6% to $38.10 after the company&#8217;s board recommended the acceptance of Asahi Kasei&#8217;s tender offer.</li>
<li>Visionary Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) rose 68% to $0.3350. Visionary Holdings said that the company has successfully transformed into a high-innovation and high growth company.</li>
<li>Oblong, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) surged 57% to $0.2841.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) rose 45.2% to $20.47.</li>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) jumped 37% to $2.1801 after the company announced results from its ovarian caner study with UPMC Magee-Womens Hospital.</li>
<li>Trinity Place Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPHS#NASDAQ">TPHS</a>) rose 35% to $0.1837.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) gained 31% to $0.4359.</li>
<li>Virgin Galactic Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) rose 30% to $1.1000.</li>
<li>Kuke Music Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KUKE#NYSE">KUKE</a>) gained 24.2% to $3.2781. Kuke Music signed a non-binding term sheet with Naxos One Holding.</li>
<li>Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) rose 22% to $38.29 after the company announced it agreed to sell its rights to its 15% royalty on potential U.S. net sales of Servier&#8217;s vorasidenib to Royalty Pharma.</li>
<li>Arcturus Therapeutics Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) gained 21% to $36.63 after the company announced it will present Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) shares rose 19.3% to $0.1205 after dipping over 10% on Friday.</li>
<li>Ocean Power Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NASDAQ">OPTT</a>) shares gained 16.7% to $0.2240 after gaining around 5% on Friday.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) gained 14.4% to $0.3411 after the company announced it has completed its at-the-market equity offering program, which was previously announced.</li>
<li>Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) climbed 13.7% to $31.20 after the company announced that its Phase 3 GRACE trial met its primary endpoint.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) rose 13% to $13.93.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) gained 11.7% to $8.68 after jumping over 16% on Friday.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) rose 10.9% to $1.0201.</li>
<li>Abacus Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) gained 10.1% to $11.78.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) rose 10.1% to $11.18.</li>
<li>HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) gained 6.9% to $631.00.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Marpai, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRAI#NASDAQ">MRAI</a>) shares fell 54.7% to $0.6468 after the company announced its intention to withdraw from the Nasdaq hearings process.</li>
<li>Innovative Eyewear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares fell 47.4% to $0.5170 after surging 428% on Friday.</li>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) fell 41% to $8.00.</li>
<li>Netcapital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>) dipped 27.7% to $0.1390 after the company announced that it entered into definitive agreement for the immediate exercise of $2.2 million of certain outstanding Series A-2 warrants.</li>
<li>OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares fell 24.4% to $1.77 after jumping 56% on Friday. OneMedNet, last week, highlighted a &#8216;five-fold expansion&#8217; of its iRWD network and platform.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) fell 22.8% to $2.61.</li>
<li>Akanda Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares fell 18.5% to $3.35 following a 72% surge on Friday. The international medical cannabis company implemented a 1-for-40 reverse stock split on its ordinary shares effective May 23, 2024, according to a recent exchange filing.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) fell 17.8% to $8.25.</li>
<li>G1 Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTHX#NASDAQ">GTHX</a>) declined 17.6% to $3.37.</li>
<li>Edible Garden AG Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) fell 15.6% to $1.8399.</li>
<li>HilleVax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) fell 13.6% to $11.14.</li>
<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) dipped 13.3% to $82.08.</li>
<li>Ryde Group Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#NYSE">RYDE</a>) declined 12.6% to $9.38.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) fell 12.4% to $13.56.</li>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) declined 12.3% to $3.52. NWTN received expected notification from the Nasdaq related to delayed annual report on Form 20-F.</li>
<li>DraftKings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) dipped 11% to $36.29 after the Illinois Senate approved a 2025 budget that includes a sports betting tax hike.</li>
<li>Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) fell 9.5% to $54.28 as the company revealed interim results for bispecific antibody petosemtamab with pembrolizumab at 2024 American Society of Clinical Oncology Annual Meeting.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) dipped 9.2% to $151.28.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) declined 9.1% to $112.24 after RBC Capital downgraded the stock from Outperform to Sector Perform.</li>
<li>Minim, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) shares fell 8.6% to $3.91 after gaining 33% on Friday.</li>
<li>Applied UV, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUVI#NASDAQ">AUVI</a>) shares fell 8.5% to $0.2879. Applied UV shares fell around 34% on Friday after the company reportedly filed for Chapter 11 bankruptcy.</li>
<li>Loar Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) declined 7% to $51.36.</li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) declined 6% to $67.75 after the company&#8217;s Shopee was reportedly accused of suspected anti-competition breaches in Indonesia.</li>
<li>Hello Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) fell 5.8% to $5.20 following first-quarter results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/39038936/1-5m-bet-on-this-healthcare-stock-check-out-these-4-stocks-insiders-are-buying">$1.5M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying</a>

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Tuesday,&nbsp;Agios Pharmaceuticals&nbsp;Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) agreed to&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g39034943/agios-announces-905-million-purchase-agreement-for-vorasidenib-royalty" rel="noreferrer noopener">sell its rights</a>&nbsp;to its 15% royalty on potential U.S. net sales of&nbsp;Servier&#8217;s&nbsp;vorasidenib&nbsp;to&nbsp;Royalty Pharma Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>).&nbsp;
Under the terms of the agreement, Agios will receive an upfront payment of $905 million upon FDA approval of&nbsp;vorasidenib, and Royalty Pharma will receive the entirety of the 15% royalty on annual U.S. net sales of&nbsp;vorasidenib&nbsp;up to $1 billion and a 12% royalty on annual U.S. net sales greater than $1 billion.&nbsp;
Agios will retain a 3% royalty on annual U.S. net sales over&nbsp;$1 billion.
Vorasidenib is an oral, selective, highly brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes for IDH-mutant diffuse glioma.&nbsp;
IDH mutant gliomas are&nbsp;the most common adult, malignant primary brain tumors diagnosed in patients younger than 50.
In 2021, Agios&nbsp;completed the&nbsp;<a target="_blank" href="https://investor.agios.com/news-releases/news-release-details/agios-announces-closing-oncology-business-sale-servier" rel="noreferrer noopener">sale</a>&nbsp;of its oncology portfolio – including&nbsp;vorasidenib&nbsp;– to Servier.&nbsp;
As part of that divestiture, Agios is owed a milestone payment of&nbsp;$200 million&nbsp;upon vorasidenib&#8217;s approval by the FDA and a 15% royalty on U.S. net sales of&nbsp;vorasidenib.&nbsp;
Agios continues to retain the right to the approval milestone from Servier.&nbsp;Servier&nbsp;<a target="_blank" href="https://www.globenewswire.com/Tracker?data=WmFHv3fOBetDObvPv98dFcI0TdPQMfkZGZsBOQn2Y9FSHwqIXnjqd6AnfnHshuuGzJh2lan9SMLrrEbFUFRtzebZDHQErRMNYYZRRS7Zc14ddrxKbYh5kqct5tBvkBMM" rel="noreferrer noopener">announced</a>&nbsp;that the FDA has designated&nbsp;a&nbsp;Prescription Drug User Fee Act (PDUFA)&nbsp;action date&nbsp;of August 20.
Earlier this year, Agios Pharmaceuticals said the Phase 3 ENERGIZE study of&nbsp;mitapivat&nbsp;in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36468800/why-is-blood-disorder-focused-agios-pharmaceuticals-stock-trading-higher-today" rel="noreferrer noopener">endpoint of hemoglobin response</a>.&nbsp;
Statistical significance was also achieved&nbsp;for both&nbsp;key&nbsp;secondary endpoints associated with a change from baseline in FACIT-Fatigue Score and hemoglobin concentration.
Price Action: AGIO shares are up 20.7% at $38.03 at last check Tuesday.
Photo via Shutterstock

U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Tuesday.
Shares of NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) rose during Tuesday's session on reports Elon Musk&#8217;s xAI plans to build a supercomputer that will power its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39037833/magnificent-7-becomes-the-magnificent-one-wall-street-guru-hails-single-tech-stock-">Grok AI chatbot</a>.
The company, last week, reported better-than-expected financial results for its first quarter and issued strong <a href="https://www.benzinga.com/24/05/38997534/nvidias-market-dominance-seems-bubbly-says-renowned-wall-street-investor-rob-arnott">guidance for the second quarter.</a>
NVIDIA shares gained 4.4% to $1,110.87 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) shares climbed 110% to $46.20 after the company announced topline results from ASPEN Phase 3 study met its primary endpoint.</li>
<li>Calliditas Therapeutics AB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALT#NASDAQ">CALT</a>) shares rose 74.6% to $38.10 after the company&#8217;s board recommended the acceptance of Asahi Kasei&#8217;s tender offer.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) shares jumped 45.2% to $20.47.</li>
<li>Virgin Galactic Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) shares surged 30% to $1.1000.</li>
<li>Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) jumped 22% to $38.29 after the company announced it agreed to sell its rights to its 15% royalty on potential U.S. net sales of Servier&#8217;s vorasidenib to Royalty Pharma.</li>
<li>Arcturus Therapeutics Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) shares rose 21% to $36.63 after the company announced it will present Phase 1 results in healthy volunteers and new Phase 1b interim data in CF patients for ARCT-032.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) climbed 14.4% to $0.3411 after the company announced it has completed its at-the-market equity offering program, which was previously announced.</li>
<li>Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) shares rose 13.7% to $31.20 after the company announced that its Phase 3 GRACE trial met its primary endpoint.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) jumped 13% to $13.93.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) rose 11.7% to $8.68 after jumping over 16% on Friday.</li>
<li>Abacus Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) climbed 10.1% to $11.78.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) gained 10.1% to $11.18.</li>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) shares climbed 8.8% to $194.12. JMP Securities analyst Andrew Boone upgraded Duolingo from Market Perform to Market Outperform and announced a price target of $260.</li>
<li>HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) rose 6.9% to $631.00.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) gained 6.4% to $122.07.</li>
<li>Pan American Silver Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NASDAQ">PAAS</a>) gained 5.2% to $22.12.</li>
<li>MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) rose 4.8% to $23.59.</li>
<li>Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) shares rose 4.7% to $16.75 after Mizuho upgraded the stock from Neutral to Buy.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/39037640/top-5-real-estate-stocks-that-could-lead-to-your-biggest-gains-this-month">Top 5 Real Estate Stocks That Could Lead To Your Biggest Gains This Month</a>

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares rose 193.0% to $0.63 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.8 million. </li>
<li>Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) shares moved upwards by 141.54% to $53.14. The company's market cap stands at $7.8 billion. </li>
<li>Calliditas Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALT#NASDAQ">CALT</a>) shares moved upwards by 71.09% to $38.36. The market value of their outstanding shares is at $1.0 billion. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) shares moved upwards by 62.45% to $2.55. The company's market cap stands at $10.4 million. </li>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) shares rose 22.42% to $33.69. The company's market cap stands at $3.5 billion. </li>
<li>Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) shares increased by 21.58% to $38.3. The market value of their outstanding shares is at $2.1 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares decreased by 31.9% to $0.67 during Tuesday's pre-market session. The market value of their outstanding shares is at $11.7 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock decreased by 18.7% to $1.87. The company's market cap stands at $44.5 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares fell 14.24% to $0.16. The market value of their outstanding shares is at $3.4 million. </li>
<li>eFFECTOR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFTR#NASDAQ">EFTR</a>) shares decreased by 13.49% to $1.54. The market value of their outstanding shares is at $7.2 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock fell 11.74% to $1.58. The company's market cap stands at $10.4 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock fell 11.2% to $3.65. The market value of their outstanding shares is at $3.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EFTR

ONCO

RNAZ

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Agios Pharmaceuticals shares are trading higher after the company announced it agreed to sell its rights to its 15% royalty on potential U.S. net sales of Servier's vorasidenib to Royalty Pharma.

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Merus (MRUS – Research Report), Royalty Pharma (RPRX...

Analysts Are Bullish on Top Healthcare Stocks: Merus (MRUS), Royalty Pharma (RPRX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sanofi (SNYNF – Research Report), Agios Pharma (AGIO...

Analysts Are Bullish on Top Healthcare Stocks: Sanofi (SNYNF), Agios Pharma (AGIO)

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Agios Pharma (AGIO – Research Report), wi...

Agios Pharma's Mitapivat Shows Promising Results: Buy Rating Affirmed with a $49.00 Price Target

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Teleflex (TFX – Research Report), Agios Pharma (AG...

Analysts Offer Insights on Healthcare Companies: Teleflex (TFX), Agios Pharma (AGIO) and CureVac (CVAC)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Wall Street regards the healthcare sector as a constant source of innovation, while <a href="https://investorplace.com/2024/05/why-the-rest-of-2024-could-be-good-for-investing-in-biotech-stocks/">biotechnology</a> stands at the pinnacle of groundbreaking medical advancements. The long-term potential of robust <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> to buy remains undeniable for investors. As the summer season kicks in, several biotech companies exhibit characteristics that could ignite this potential summertime surge. Promising clinical trial results, significant product launches, or strategic partnerships could drive this momentum.



We should note that the benchmark S&amp;P 500 index has notably gained nearly 12% year-to-date (YTD). Conversely, the SPDR S&amp;P Biotech ETF (NYSEARCA:<a href="https://investorplace.com/stock-quotes/xbi-stock-quote/">XBI</a>) has underperformed in the broader market, gaining only 1% YTD. This disparity suggests the potential for a catch-up rally within the biotechnology sector. With that information, here are three biotech stocks to buy that could be prime candidates for significant growth in the second half of 2024.



<h2>BioMarin Pharmaceuticals (BMRN) </h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/11/bmrn1600-300x169.png" alt="Person holding smartphone with logo of U.S. company BioMarin Pharmaceutical Inc. (BMRN) on screen in front of website. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>First up on our list of biotech stocks to buy is BioMarin Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/bmrn-stock-quote/">BMRN</a>). This biotechnology company focuses on innovative therapies for rare genetic disorders, specializing in enzyme replacement therapies (ERTs). These therapies address the underlying cause of these conditions by introducing healthy copies of the deficient gene.



BioMarin reported strong <a href="https://investors.biomarin.com/news/news-details/2024/BioMarin-Reports-Record-Financial-Results-for-the-First-Quarter-2024/default.aspx">financial results for the first quarter of 2024</a>. Total revenues climbed 9% year-over-year (YOY) to $648.8 million, fueled by a surge in demand for their key drug, Voxzogo. Sales of this therapy skyrocketed 74%, driving higher gross profit margins and a 21% YOY jump in net income to $139.7 million. Furthermore, adjusted diluted earnings per share (EPS) rose 18% YOY to $0.71.



Meanwhile, BioMarin <a href="https://investors.biomarin.com/news/news-details/2024/New-Data-for-BioMarins-VOXZOGO-vosoritide-for-Multiple-Growth-Related-Conditions-in-Children-Presented-at-Pediatric-Endocrine-Society-PES-Annual-Meeting/default.aspx">presented positive new data</a> supporting the safety and efficacy of Voxzogo at the Pediatric Endocrine Society meeting. In addition, BioMarin&rsquo;s Phase 3 data confirmed significant gains in annualized growth velocity for achondroplastic children.



So far in 2024, BMRN stock has tumbled more than 22%. &nbsp;The shares are trading at 28.25 times forward earnings and 5.86 times sales. Finally, analysts have a <a href="https://edition.cnn.com/markets/stocks/bmrn">12-month price target</a> of $110 for BMRN, signaling a 44% upside.



<h2>Alnylam Pharmaceuticals (ALNY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/alny1600-300x169.png" alt="Illustrative Editorial of Alnylam Pharmaceuticals Inc website homepage. Alnylam Pharmaceuticals Inc logo visible on display screen. ALNY stock"><div>Source: Pavel Kapysh / Shutterstock.com</div></div>A pioneer in the field of RNA interference (RNAi) therapeutics, Alnylam Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/alny-stock-quote/">ALNY</a>) is our next name among the biotech stocks to buy. RNA interference (RNAi) technology offers a revolutionary approach to treating diseases by silencing specific genes contributing to pathological processes. Alnylam employs RNAi to develop therapeutics for diverse cardiovascular, metabolic, infectious and neurological diseases.



In the <a href="https://investors.alnylam.com/press-release?id=28136">first quarter of 2024</a>, Alnylam Pharmaceuticals reported strong financial results. The company achieved $365 million in revenue, marking a 32% YOY growth compared to last year. This growth was primarily driven by a 39% increase in total demand in the U.S., largely due to the strong uptake of Amvuttra, used to treat <a href="https://www.goodrx.com/amvuttra/what-is">nerve damage</a>.



Elsewhere, management <a href="https://investors.alnylam.com/press-release?id=28111">announced positive results</a> from Alnylam&rsquo;s Kardia-2 Phase 2 clinical trial evaluating zilebesiran, a potential treatment for hypertension. Investors noted that a single dose of zilebesiran significantly reduced blood pressure in patients with inadequately controlled hypertension. 



Despite positive developments, ALNY stock has dropped around 22% YTD and is trading 9.29 times sales. On the other hand, Wall Street has a <a href="https://edition.cnn.com/markets/stocks/alny">12-month median price forecast</a> of $217.5 for ALNY, suggesting more than a 45% upside.



<h2>Royalty Pharma (RPRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>We are completing our discussion of buying biotech stocks at Royalty Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/rprx-stock-quote/">RPRX</a>).&nbsp;The company, in part, acts as a financier for developing innovative drugs by providing upfront capital to pharmaceutical and biotechnology companies. In exchange, the company receives future royalty payments based on the product&rsquo;s sales. &nbsp;



Royalty Pharma reported robust performance in the first quarter of 2024, with Royalty Receipts growing 14% YOY to $705 million. Strong royalties on Evrysdi, Trelegy and the cystic fibrosis franchise drove this growth. However, Portfolio Receipts declined 37% to $717 million, reflecting a $475 million milestone payment received in the first quarter of 2023.



In May 2024, Royalty Pharma <a href="https://www.royaltypharma.com/news/royalty-pharma-and-agios-pharmaceuticals-enter-into-vorasidenib-royalty-agreement-for-905-million/">acquired an interest</a> in Agios Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/agio-stock-quote/">AGIO</a>) royalty on Vorasidenib for $905 million. Vorasidenib is a potential treatment for IDH-mutant glioma, a progressive and incurable brain tumor. Additionally, RPRX <a href="https://www.royaltypharma.com/news/royalty-pharma-and-cytokinetics-announce-expanded-strategic-funding-collaboration-totaling-up-to-575-million-to-support-commercial-launch-of-aficamten-and-to-advance-rd-pipeline/">partnered with</a> Cytokinetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cytk-stock-quote/">CYTK</a>) on a $575 million deal. This collaboration includes support for the commercial launch of Aficamten, a heart failure treatment.



So far in 2024, RPRX stock has lost over 2%, while the shares are trading at 9.11 times forward earnings and 7.35 times sales. Finally, analysts have a <a href="https://edition.cnn.com/markets/stocks/RPRX">12-month price target</a> of $43.05 for RPRX, signaling a 57% upside.



On the date of publication, Tezcan Gecgil did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>Tezcan Gecgil, PhD, began contributing to InvestorPlace in 2018. She brings over 20 years of experience in the U.S. and U.K. and has also completed all 3 levels of the Chartered Market Technician (CMT) examination. Publicly, she has contributed to <a href="https://www.investing.com/">investing.com</a> and the U.K. website of <a href="https://www.fool.com/">The Motley Fool.</a></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/junes-biotech-boom-3-stocks-to-buy-for-a-summertime-surge/">June&#8217;s Biotech Boom: 3 Stocks to Buy for a Summertime Surge</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge

Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Doximity (DOCS – Research Report), Agios Pharma (AGIO – Research ...

Analysts Conflicted on These Healthcare Names: Doximity (DOCS), Agios Pharma (AGIO) and CSL (OtherCMXHF)

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Agios Pharma (AGIO – Research Report) today and set a price target of $55.00. ...

Piper Sandler Keeps Their Buy Rating on Agios Pharma (AGIO)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Galapagos (GLPG – Research Report), Agios Pharma (AG...

Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Agios Pharma (AGIO) and Viking Therapeutics (VKTX)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Government Trades

Agios Pharmaceuticals Inc

top performing AGIO trades